NASDAQ:ASMB Assembly Biosciences (ASMB) Stock Price, News & Analysis $10.53 +0.12 (+1.15%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Assembly Biosciences Stock (NASDAQ:ASMB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Assembly Biosciences alerts:Sign Up Key Stats Today's Range$10.41▼$10.7150-Day Range$8.26▼$13.3152-Week Range$7.75▼$19.93Volume15,021 shsAverage Volume25,666 shsMarket Capitalization$79.01 millionP/E RatioN/ADividend YieldN/APrice Target$33.00Consensus RatingModerate Buy Company OverviewAssembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Read More… Assembly Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreASMB MarketRank™: Assembly Biosciences scored higher than 82% of companies evaluated by MarketBeat, and ranked 202nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAssembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAssembly Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Assembly Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Assembly Biosciences are expected to decrease in the coming year, from ($6.87) to ($7.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assembly Biosciences is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assembly Biosciences is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssembly Biosciences has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Assembly Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.43% of the float of Assembly Biosciences has been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assembly Biosciences has recently decreased by 17.39%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAssembly Biosciences does not currently pay a dividend.Dividend GrowthAssembly Biosciences does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.71 Percentage of Shares Shorted0.43% of the float of Assembly Biosciences has been sold short.Short Interest Ratio / Days to CoverAssembly Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Assembly Biosciences has recently decreased by 17.39%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment1.60 News SentimentAssembly Biosciences has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Assembly Biosciences this week, compared to 7 articles on an average week.Search InterestOnly 1 people have searched for ASMB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Assembly Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,726.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Assembly Biosciences is held by insiders.Percentage Held by InstitutionsOnly 19.92% of the stock of Assembly Biosciences is held by institutions.Read more about Assembly Biosciences' insider trading history. Receive ASMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ASMB Stock News HeadlinesAssembly Biosciences announces data from herpes simplex virus programApril 9, 2025 | markets.businessinsider.comAssembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID CongressApril 9, 2025 | globenewswire.comTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you ready for it?April 24, 2025 | Porter & Company (Ad)Assembly Biosciences initiated with a Buy at GuggenheimMarch 26, 2025 | markets.businessinsider.comGuggenheim starts Assembly Biosciences with a Buy ahead of clinical readoutsMarch 26, 2025 | markets.businessinsider.comGuggenheim Initiates Coverage of Assembly Biosciences (ASMB) with Buy RecommendationMarch 26, 2025 | msn.comAssembly Biosciences files $250M mixed securities shelfMarch 21, 2025 | markets.businessinsider.comAssembly Biosciences Reports Year End 2024 Financial Results and Recent HighlightsMarch 20, 2025 | globenewswire.comSee More Headlines ASMB Stock Analysis - Frequently Asked Questions How have ASMB shares performed this year? Assembly Biosciences' stock was trading at $15.78 at the start of the year. Since then, ASMB shares have decreased by 33.3% and is now trading at $10.53. View the best growth stocks for 2025 here. How were Assembly Biosciences' earnings last quarter? Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings data on Thursday, March, 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.75) by $0.18. The biopharmaceutical company had revenue of $7.36 million for the quarter, compared to analyst estimates of $7.05 million. Assembly Biosciences had a negative net margin of 144.05% and a negative trailing twelve-month return on equity of 121.46%. When did Assembly Biosciences' stock split? Assembly Biosciences shares reverse split on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Assembly Biosciences' major shareholders? Assembly Biosciences' top institutional shareholders include Palumbo Wealth Management LLC (0.24%). Insiders that own company stock include Alexander Schornstein, John G Mchutchison, Jason A Okazaki, Nicole S White, Michael P Samar, William E Iv Delaney, Jeanette M Bjorkquist and Michael Houghton. View institutional ownership trends. How do I buy shares of Assembly Biosciences? Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Assembly Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assembly Biosciences investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings3/20/2025Today4/24/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ASMB CIK1426800 Webwww.assemblybio.com Phone(833) 509-4583Fax646-706-5101Employees100Year Founded2005Price Target and Rating Average Stock Price Target$33.00 High Stock Price Target$35.00 Low Stock Price Target$31.00 Potential Upside/Downside+217.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($6.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-61,230,000.00 Net Margins-144.05% Pretax Margin-142.50% Return on Equity-121.46% Return on Assets-34.56% Debt Debt-to-Equity RatioN/A Current Ratio2.36 Quick Ratio2.36 Sales & Book Value Annual Sales$28.52 million Price / Sales2.73 Cash FlowN/A Price / Cash FlowN/A Book Value$7.50 per share Price / Book1.39Miscellaneous Outstanding Shares7,503,000Free Float6,032,000Market Cap$77.99 million OptionableOptionable Beta0.65 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:ASMB) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.